Global Dry Eye Disease Market Report 2022: Increasing Emergence of Novel Treatments Presents Opportunities
December 20, 2022 08:33 ET
|
Research and Markets
Dublin, Dec. 20, 2022 (GLOBE NEWSWIRE) -- The "Global Dry Eye Disease Market By product, By distribution channel & By region-Forecast Analysis 2022-2028" report has been added to ...
Ophthalmic Drugs Market to Develop at CAGR of 6.83% during Forecast Period: TMR Study
November 16, 2022 13:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - In 2021, the value of the ophthalmic drugs market stood at US$ 26.46 Bn. Analysis of...
Global Dry Eye Treatment Devices Market Report 2022: High Incidence & Prevalence of Dry Eye Diseases Boosting Sector
November 08, 2022 06:48 ET
|
Research and Markets
Dublin, Nov. 08, 2022 (GLOBE NEWSWIRE) -- The "Global Dry Eye Treatment Devices Market Size, Share & Industry Trends Analysis Report by Technology, End-user, Regional Outlook and Forecast,...
Vaccentis strengthens leadership with appointment of Mario Stark as Chief Sales and Marketing Officer
September 08, 2022 02:00 ET
|
Vaccentis AG
Life science executive with experience in ophthalmology, branding, marketing and financingWill lead sales and marketing of medicines for dry eye and autoimmune diseases Zurich, Switzerland,...
Outlook on the OTC Artificial Tears Global Market to 2027 - Development of Novel Approach Presents Opportunities
August 16, 2022 05:03 ET
|
Research and Markets
Dublin, Aug. 16, 2022 (GLOBE NEWSWIRE) -- The "Global OTC Artificial Tears Market (2022-2027) by Product, Container Type, Formulation, Application, Distribution Channel, Geography, Competitive...
AXIM Biotechnologies Celebrates Feature on the Vision is More Than 20/20™ Podcast
July 21, 2022 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular...
Xequel Bio Announces Positive Results from Phase 1b Study of iNexin™, a Novel aCT1 Ophthalmic Solution
July 14, 2022 09:00 ET
|
Xequel Bio, Inc.
Excellent Safety and Tolerability Profile for iNexin™ for the Treatment of Corneal Injury Early Efficacy Signals Provide Rationale to Advance to Phase 2 Proprietary aCT1 Platform to Address Unmet...
Vaccentis stärkt Management durch Berufung von Martin Munte zum CEO
July 12, 2022 02:00 ET
|
Vaccentis AG
Pharmamanager mit langjährige Führungserfahrung bei Amgen, AstraZeneca und RocheWeitere Verstärkung des Managements nach Ernennung dreier neuer Mitglieder im Verwaltungsrat Zurich, Schweiz, 12....
Vaccentis appoints Martin Munte as CEO and strengthens Board
July 12, 2022 02:00 ET
|
Vaccentis AG
Martin Munte has extensive leadership experience at Amgen, AstraZeneca and RocheStrengthening management after appointment of three new Board members Zurich, Switzerland, July 12, 2022 -...
AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures
May 24, 2022 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface...